Tovorafenib is a Small Molecule owned by Takeda Pharmaceutical, and is involved in 5 clinical trials, of which 4 are ongoing, and 1 is planned.

TAK-580 (MLN2480) is a pan-Raf kinase inhibitor that selectively inhibits both monomeric and dimeric RAF kinase. Raf kinase inhibitor protein is a member of the phosphatidylethanolamine-binding protein family. pan-Raf kinase inhibitor acts by blocking the enzyme RAF kinase, which is a critical component of the RAF/MEK/ERK signaling pathway that controls cell division and proliferation. Raf kinase is an enzyme in the Ras pathway. RAS mutations may result in constitutive activation of the RAS/RAF/MEK/ERK kinase signaling pathway and have been found to occur frequently in human tumors.

The revenue for Tovorafenib is expected to reach a total of $313m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Tovorafenib NPV Report.

Tovorafenib was originated by Biogen and Viracta Therapeutics and is currently owned by Takeda Pharmaceutical. Day One Biopharmaceuticals is the other company associated in development or marketing of Tovorafenib.

Tovorafenib Overview

Tovorafenib (TAK-580 (MLN2480)) is under development for the treatment of solid tumors such as glioma, melanoma, relapsed pediatric low-grade glioma, Langerhans-cell histiocytosis, craniopharyngioma and malignant glioma. It is administered through oral route. The drug candidate acts by targeting pan-Raf kinases A-Raf, B-Raf and C-Raf. It was also under development for the treatment of solid tumors like metastatic melanoma and non-small cell lung cancer.

Day One Biopharmaceuticals Overview

Day One Biopharmaceuticals (Day One) is a biopharmaceutical company. It discovers and develops drugs for addressing the unmet medical needs of cancers associated with genetic mutations in rapidly accelerated fibrosarcoma (RAF) family kinases. The company is investigating its lead product candidate: DAY101 (TAK-580), a pan-RAF inhibitor for the treatment of low-grade glioma and cancers that foster genetic alterations in RAF. It works in partnership with research and the parent advocacy communities to advance the development of medicines for the treatment of various cancer types. Day One is headquartered in South Brisbane, California, the US.

The operating loss of the company was US$72.7 million in FY2021, compared to an operating loss of US$13.8 million in FY2020. The net loss of the company was US$170.6 million in FY2021, compared to a net loss of US$40.5 million in FY2020.

Quick View – Tovorafenib

Report Segments
  • Innovator
Drug Name
  • Tovorafenib
Administration Pathway
  • Oral
Therapeutic Areas
  • Genetic Disorders
  • Oncology
Key Companies
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.